These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6166445)

  • 41. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Conservative therapy of prostatic hyperplasia with urinary retention].
    Djulepa J
    Med Welt; 1983 Dec; 34(48):1377-9. PubMed ID: 6197601
    [No Abstract]   [Full Text] [Related]  

  • 43. Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile.
    Crawford ED
    BJU Int; 2005 Jun; 95 Suppl 4():1-5. PubMed ID: 15871729
    [No Abstract]   [Full Text] [Related]  

  • 44. [Semiology of urination disorders in men].
    Serment G; Rattier C
    Rev Prat; 1995 Feb; 45(3):292-8. PubMed ID: 7536955
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Modern algorithm of examination and treatment of patients with prostatic adenoma].
    Pushkar' DIu; Rasner PI
    Urologiia; 2007; (3):87-94. PubMed ID: 17722625
    [No Abstract]   [Full Text] [Related]  

  • 46. [Benign prostatic hyperplasia; recommendations for transmural care. Working Group, Dutch College of General Practitioners and Netherlands College of Urologists].
    Klomp ML; Rosmalen CF; Romeijnders AC; Oosterhof GO; Schlatmann TJ
    Ned Tijdschr Geneeskd; 1998 Nov; 142(47):2563-8. PubMed ID: 10028352
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Value of flow measurements in the evaluation of lower urinary obstruction in man].
    Susset G; Elhilali M; Shoukry I; Dutartre D
    J Urol Nephrol (Paris); 1973 Dec; 79(12 Pt 2):594-601. PubMed ID: 4140923
    [No Abstract]   [Full Text] [Related]  

  • 48. [Urination disorders caused by prostatic hyperplasia. Effect of Bazoton, Harzol and Prosta-capsules].
    Hallwachs O
    MMW Munch Med Wochenschr; 1981 Oct; 123(44):1675-6. PubMed ID: 6171728
    [No Abstract]   [Full Text] [Related]  

  • 49. [Benign prostate syndrome: urinary tract symptoms can be eased with phytotherapy].
    Popa G; Hägele-Kaddour H; Walther C
    MMW Fortschr Med; 2005 Aug; 147(33-34):42. PubMed ID: 16138635
    [No Abstract]   [Full Text] [Related]  

  • 50. The urodynamic assessment of benign prostatic hyperplasia obstruction.
    Artibani W
    J Urol (Paris); 1995; 101(1):42-4. PubMed ID: 7545728
    [No Abstract]   [Full Text] [Related]  

  • 51. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The American Urological Association symptom index--concerns and confirmation.
    Roehrborn CG
    J Urol; 1996 Jun; 155(6):1975-6. PubMed ID: 8618300
    [No Abstract]   [Full Text] [Related]  

  • 54. A critique of scoring systems.
    Abrams P
    Prog Clin Biol Res; 1994; 386():109-23. PubMed ID: 7528381
    [No Abstract]   [Full Text] [Related]  

  • 55. [Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia].
    de la Taille A
    Prog Urol; 2008 Apr; 18 Suppl 3():S53-7. PubMed ID: 18455085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluating symptoms and functional status in benign prostate hyperplasia.
    O'Leary MP
    Br J Urol; 1995 Jul; 76 Suppl 1():25-8. PubMed ID: 7544212
    [No Abstract]   [Full Text] [Related]  

  • 57. [Current possibilities in the treatment of prostatic hypertrophy].
    Novak R
    Lijec Vjesn; 1975 Feb; 97(2):111-2. PubMed ID: 51458
    [No Abstract]   [Full Text] [Related]  

  • 58. [Prostatilen effects on voiding disorders in patients with benign prostatic hyperplasia].
    Al'-Shukri SKh; Gorbachev AG; Borovets SIu; Belousov VIa; Kuz'min IV
    Urologiia; 2005; (5):25-6. PubMed ID: 16281835
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Benign prostatic hyperplasia.
    McConnell JD
    J Urol; 1994 Aug; 152(2 Pt 1):459-60. PubMed ID: 7516980
    [No Abstract]   [Full Text] [Related]  

  • 60. [Safety ov benign prostatic hyperplasia treatment with alpha-adrenoblocker dalphas].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2000; (2):3-5. PubMed ID: 11186726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.